




MINI Act

Advocacy Toolkit





Background

The Maintaining Investments in New Innovation, or MINI, Act (H.R. 1672) is bipartisan legislation that supports the development of genetically targeted technologies (GTTs).

Known as GTTs, these medications put Nobel Prize-winning science to use combatting disease at a genetic level.

The MINI Act would give GTTs appropriate and fair treatment under the Medicare Drug Price Negotiation Program. The legislation would classify GTTs more like biologics by allowing 11 years, rather than seven, before they become subject to drug price negotiation.

The shift could incentivize and protect innovative research and development on GTTs that treat disease states with a high level of unmet need, including rare, cardiovascular and neurological diseases.

Table of Contents

Messaging Pillars	3
What You Can Do	5
Social Media	6
Letter Desk	7

Messaging Pillars



The MINI Act provides the policy stability needed for companies to take the risk on this early-stage and next generation science.

GTTs are pushing the bounds of science to change the course of disease.

- GTTs rely on new scientific approaches to get at the root causes of disease rather than symptoms.
- The first treatment using this technology was approved only 10 years ago, and only 19 GTTs are currently on the market.
- Some function by finding and turning off the specific gene that causes the disease, allowing the body's natural systems to break it down. Others modify RNA molecules to fix genetic issues in the body.
- This is a new generation of medicine. Developing GTTs requires a highly controlled, complex process that can take more than a decade.
- It is a risky endeavor without any guarantee that the treatment will eventually make it to patients.



The MINI Act supports innovative medicines that help prevent disease progression, reduce hospitalizations and have the potential to lower long-term health care spending.

GTTs treat the root cause of disease, lowering downstream costs.

- If we can treat diseases before they progress, before they cause major medical events or other diseases, we can save patients and the health care system money.
- By essentially pausing the disease, GTTs can help patients avoid more severe symptoms that require more intensive and expensive treatment down the line.
- GTTs are also typically long acting, meaning they are often easier for patients to adhere to, avoiding costly medical events that result from not taking medications as prescribed.
- Development of this next generation of medicine will help reduce strain on our health care system.



The MINI Act supports the development of a new approach to medicine that has the potential to change the course of treatment for many patient populations.

GTTs are being explored across a wide variety of diseases, with the potential to treat many.

- The development of GTTs has the potential to change the course of many diseases—not just a few.
- GTTs have the potential to target some of the areas of greatest unmet medical need, such as ALS, hemophilia, amyloidosis and other rare genetic diseases.
- They also have the potential to fundamentally change the standard of care for more common diseases such as high cholesterol and cardiovascular disease.
- Plus, GTTs can cross the blood brain barrier like small-molecule medications, unlocking great potential for the treatment of neurological diseases including Alzheimer's.
- Diverse patient populations around the country could benefit from this next generation of medicine.



The MINI Act encourages investment in GTTs here, helping the United States remain the global leader and ensuring Americans will get access to them more quickly than patients in other countries.

GTTs are the future. Investing in them here keeps the United States at the forefront of medical innovation.

- The United States is the global leader in biomedical innovation, providing a policy and regulatory environment that supports complex R&D.
- Americans have the most treatment options and access to more new medicines faster than any other country.
- We need to ensure our system continues to support R&D, particularly to fuel the development of the next generation of medicine like GTTs.
- China and Japan are emerging as strong competitors to the United States, implementing pro-innovation policies to attract investment in life sciences.
- The United States cannot cede its leadership to other countries, risking the economic benefits of the pharmaceutical industry and the faster access for American patients.

What You Can Do



Events



Fly-ins / Direct
Hill Advocacy



Hill Briefings



Link to Action Alert /
Letter Desk



Op-Eds



One-Pagers



Panels



Patient Videos



Proclamations



Share Hill
Newsletter



Sign-On Letters



Targeted Ads



Webinars



Social Media



[Insert group handle here] is proud to support the MINI Act. This legislation will help expand access to care for women nationwide. You can take action too — **ask your Member of Congress** to support the **#MINIAct**. **#SupportTheMINI**



Heart disease innovation cannot slow down when patients need it most. The MINI Act can help protect progress in genetically targeted technologies that may change what is possible for people living with high cardiovascular risk. **#MINIAct #HeartHealth #GTTs**

For people living with neurologic disease, innovation is not abstract. It is hope for better treatment, better function and more time. Congress should support the MINI Act and help keep genetically targeted technologies moving forward. **#MINIAct #Neurology #MedicalInnovation**



Rare disease patients know that every delay has a cost. The MINI Act would help preserve momentum behind genetically targeted technologies that could open the door to new options for communities that have waited far too long. **#MINIAct #RareDisease #GTTs**



From inherited cholesterol disorders to other serious heart conditions, patients need policies that keep breakthrough science moving. The MINI Act is a smart step to support continued progress in genetically targeted technologies. **#MINIAct #PatientAccess**

Genetically targeted technologies are shaping the future of care across disease states, from heart disease to neurologic and rare conditions. Congress should pass the MINI Act and help make sure innovation does not stall before patients benefit. **#MINIAct #PatientsFirst**

Key Hashtags

#MINIAct

#GTTs

#SupportTheMINI

#PatientAccess

Letter Desk

Use the [MINI Act letter desk](#) to make outreach to Congress easy for your network. Share it with advocates, partners and supporters so they can quickly send a message to their lawmakers and build support for the bill.

Ensuring Patient Access to Cutting-Edge Medical Innovation

Medical innovation like genetically targeted technologies powers the next generation of treatments and cures. Treatments like GTTs use Nobel Prize-winning science and can reduce patients' number of pharmacy visits, simplify medication routines, and ultimately improve patients' heart health management.

But for more patients to benefit, Congress needs to pass the bipartisan MINI Act. This legislation allows more time for research, investment and infrastructure for genetically targeted technologies. Tell your representatives: Pass the MINI Act.

[View Letter Desk ▶](#)

Dear [Lawmaker],

I am writing as a concerned constituent about access to life-changing medical treatment.

Treatments like genetically targeted technologies can reduce the number of times patients need to go to the pharmacy or take medication. They can also treat the root cause of disease, rather than just the symptoms. But the novel science behind these treatments needs time and investment.

That's why supporting MINI Act, HR 1672, is so important.

The MINI Act would fix part of the 2022 Inflation Reduction Act that treats genetically targeted technologies differently than complex biologics, despite their similarities. The oversight could have serious unintended consequences, such as discouraging investment in genetically targeted technologies just as they are taking off. Correcting the provision, on the other hand, would allow more time for these medications to go to work for patients.

Right now, only 19 genetically targeted technologies are available, including treatments for rare diseases like amyloidosis and inherited heart conditions like familial hypercholesterolemia. More of these life-changing technologies would give patients their life back.

For some patients, genetically targeted technologies offer an option where none existed before.

I hope I can count on your support for the MINI Act today.

Sincerely,

MINI Act

Advocacy Toolkit

